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Abstract
Background: Pancreatic cancer is an aggressive malignancy characterized by low responsiveness
to chemotherapy and radiotherapy. This resistance is partly due to the overexpression of several
tyrosine kinase receptors and their ligands. STI571 has specific activity in inhibiting c-kit, PDGF and
Abl receptor tyrosine kinases and has proven successful in the treatment of CML and GIST
patients. Here, we investigated the potential role of STI571 in pancreatic cancer.
Results: The GI50 of STI571 as well as the effects of STI571 on growth factor actions in pancreatic
cell lines were analyzed using the MTT assay. FACS analysis using Annexin and PI staining was
performed to study cell cycle, apoptosis, and cell death. Western blot analysis was carried out to
investigate MAP kinase and receptor tyrosine kinase phosphorylation. STI571 inhibited cell
proliferation in pancreatic cancer cell lines with GI50 concentrations ranging from 17 to 31.5
microM. EGF, IGF-1, and FGF-2 but not PDGF exerted growth stimulatory effects in pancreatic
cancer cell lines. STI571 only partly blocked these effects on cell growth, and did not abrogate
growth factor-induced receptor and MAPK phosphorylation.
Conclusion: Our data demonstrate that STI571 inhibits pancreatic cancer cell growth with high
GI50 concentrations through tyrosine-kinase receptor independent pathways. The clinical
application of STI571 in pancreatic cancer is therefore rather doubtful.
Background
Although pancreatic cancer has an incidence of only
about 10 cases/100,000 persons, it is the fourth to fifth
leading cause of cancer-related deaths in the Western
world [1]. Most of the newly diagnosed patients present at
an already unresectable tumor stage. The 5-year survival
rate of these patients is less than 1% [2–4] and the median
survival time is approximately 5–6 months after tumor
detection. One of the reasons for this is that conventional
oncological strategies, such as chemotherapy, radiother-
apy, antihormonal modalities or systemic use of mono-
clonal antibodies, have not achieved significant
improvement in the survival of pancreatic cancer patients
[5–9].
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In recent years, increasing attention has been directed
towards the role of growth factors in the pathogenesis of
human tumors. Human pancreatic cancers overexpress a
number of important tyrosine kinase growth factor recep-
tors and their ligands, such as those belonging to the epi-
dermal growth factor (EGF), fibroblast growth factor
(FGF), insulin-like growth factor (IGF-1), and vascular
endothelial growth factor (VEGF) families [10,11]. In
addition, expression of both PDGF and PDGF receptors
(PDGFRs) has been observed in pancreatic cancer [12]. It
is thought that these growth factors act in an autocrine
and/or paracrine manner to stimulate pancreatic cancer
growth. Binding of growth factors to their receptors results
in receptor autophosphorylation and subsequent signal
transduction via an array of different molecules.
Small molecule drugs that can selectively inhibit tyrosine
kinases are likely to be of benefit in a number of neoplas-
tic diseases. Although tyrosine kinase inhibitors have been
studied for many years, they often had little specificity and
thus were unlikely to be suitable for clinical applications.
Recently, more selective tyrosine kinase inhibitors have
been developed, one of them being STI571 (Gleevec,
imatinib mesylate and also known as CGP57148B;
Novartis Pharmaceuticals). STI571 belongs to the 2-phe-
nylaminopyrimidine class, and has selectivity for Abl,
PDGF receptor [13–15] and c-kit receptor tyrosine kinases
[16]. The effectiveness of this drug in blocking Bcr-Abl and
c-kit tyrosine kinases has led to Food and Drug Adminis-
tration (FDA) approval for the treatment of Philadelphia
chromosome-positive chronic myelogenous leukemia
and c-kit-positive gastrointestinal stromal tumors.
It has been shown recently that the stem cell factor (SCF)
and its receptor c-kit are present in both normal and pan-
creatic cancer tissues, and that SCF has no growth-pro-
moting effect in pancreatic cancer cells. Nevertheless,
STI571 could inhibit pancreatic cell growth dose-depend-
ently [17]. Since most human pancreatic cancer tissues
express PDGFR, STI571 might exert its function through
this pathway in pancreatic cancer cells. The purpose of this
study was to gain insight into the mechanisms of STI571
action in pancreatic cancer cells, with special emphasis on
receptor tyrosine kinase signaling.
Results
Determination of the GI50 concentration of STI571 in 
pancreatic cancer cells
To determine the GI50 concentration of STI571, pancreatic
cancer cells grown in 10% FBS- containing medium were
exposed to different doses of STI571. As seen from Table
1 and Figure 1, STI571 inhibited the growth of all tested
pancreatic cancer cells in a dose-dependent manner. The
concentrations of STI571 required to inhibit cell growth
by 50% (GI50) were in the range of 17–31.5 µM, with
Colo-357 cells being the most sensitive (17 µM), and
Aspc-1 cells the most resistant (31.5 µM) (Table 1 and Fig-
ure 1). Thus, the GI50 for pancreatic cells appeared to be
higher than the GI50 for other reported cancer cells, such
as small cell lung cancer cells, and out of the range of the
STI571 plasma concentration reported in patients treated
with this drug under clinical conditions [18,19]. Since
effects of STI571 were reported to depend on serum con-
centration, we also tested the GI50 of STI571 under low
serum conditions (1% FCS). Here, GI50 concentrations
ranged between 9 and 20 µM, with Mia-PaCa-2 cells being
the most sensitive (9 µM), and Aspc-1 cells the most resist-
ant (20 µM) (Figure 1). Therefore, increasing concentra-
tion of growth factors in serum increased the resistance of
pancreatic cancer cells to STI571.
Mechanism of STI 571 action on pancreatic cancer cells
In the next set of experiments, we evaluated the contribu-
tion of cytotoxic and cytostatic components to STI571-
Table 1: GI50 concentration of STI571 in different cancer cell lines in comparison to STI571 plasma concentrations. # as determined in 
complete medium.
cancer cell lines STI571 (µM)
Aspc-1# 31.5
BxPc-3# 21
Capan-1# 19
Colo-357# 17
Mia-PaCa-2# 26
T3M4# 25
lung cancer (6 cell lines) [16] ~5
lung cancer (A549 cell line) [32] 2–3
colorectal cancer (HT29) [34] 6
CML (K562 cell lines) [35] 0.56
STI571 plasma levels[19] 0.17–5.68Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/32
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Effect of STI571 on pancreatic cancer cell lines Figure 1
Effect of STI571 on pancreatic cancer cell lines. Aspc-1, BxPc-3, Capan-1, Colo-357, Mia-PaCa-2 and T3M4 cells were 
cultured in medium containing 1% FCS (open triangle) or 10% FCS (solid circle) and incubated in the absence (0) or presence 
of increasing concentrations of STI571 for 48 hours. Cell growth was determined by the MTT assay. Percent growth inhibition 
was calculated by comparison with control cell growth. Values shown are the mean ± SEM obtained from three independent 
experiments.
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induced growth inhibition. First, PI staining of cells was
performed in order to determine whether cell death
occurred in the treated cultures. Results presented in Fig-
ure 2 demonstrate that STI571exerted potent toxic effects
towards pancreatic cancer cells: 33.7 ± 16.5% in Mia-
PaCa-2 and 26.8% ± 16.5% in T3M4 cultures as compared
to 10.7% ± 2.5% and 5.7% ± 2.8% in control cultures,
respectively (p < 0.05). Second, simultaneous annexin V/
propidium iodide staining was employed to clarify the
type of cell death taking place in the cultures. Although we
observed progressive accumulation of annexin V-positive
cells (Figure 2), the role of apoptosis as a possible mecha-
nism of STI571-induced cell death was not further sup-
ported by the results of PI staining of nuclear DNA (Figure
2). Third, we performed cell cycle analysis of STI571-
treated pancreatic cancer cell lines, which did not reveal
any significant changes in the cell cycle pattern after 48
hours of incubation when compared to untreated cells.
Apparently, STI571 treatment caused membrane altera-
tions, leading to the layer flipping and phosphatidylserine
translocation, but did not induce caspase-dependent DNA
fragmentation. The exact mechanisms of the STI571-
induced toxicity towards pancreatic tumor cells remain to
be determined
Effects of STI571 on growth factor-induced proliferation of 
pancreatic cancer cells
Pancreatic cancer is characterized by profound distur-
bances of growth factor signaling pathways. Therefore, we
next investigated which particular pathway can be inhib-
ited by STI571 in pancreatic cancer cell lines. Mia-PaCa-2
and T3M4 cell lines were exposed to different growth fac-
tors (PDGF, EGF, FGF-2, IGF-1) in the absence or presence
of STI571 (at GI50 concentration) for 72 hours and cell
growth was assessed by MTT assays (Figure 3). EGF-
induced proliferation of both Mia-PaCa-2 and T3M4 cell
lines in a dose-dependent manner was seen with maximal
effects of +72% ± 7.5% (Mia-PaCa-2) and +52% ± 23%
(T3M4). Interestingly, STI571 partially blocked EGF-
induced cell growth, with maximal effects reduced to
+29% ± 15% (Mia-PaCa-2) and +16% ± 24% (T3M4) fol-
lowing STI571 addition (Figure 3). FGF-2 markedly stim-
ulated cell growth in Mia-PaCa-2 cell lines with maximal
effects of +79% ± 6%, and only slightly stimulated T3M4
cell lines, with maximal effects of +7% ± 4%. STI571 also
partly blocked FGF-2 induced cell growth, with maximal
effects reduced to +28% ± 7% (Mia-PaCa-2) and 2% ± 3%
(T3M4) (Figure 3). Both cell lines were less sensitive to
IGF-1 stimulation compared with EGF and FGF-2, with
maximal effects of +24% ± 2% in Mia-PaCa-2 and +17%
± 4% in T3M4. In addition, STI571 had no significant
inhibitory effects on IGF-1-induced proliferation (Figure
3). PDGF did not induce cell proliferation in Mia-PaCa-2
or T3M4 cell lines. Furthermore, in three additional cell
lines (BxPc-3, Colo-357 and Capan-1), PDGF also had no
effect on cell growth. Thus, although PDGF-mediated
growth pathways do not seem to play a role in pancreatic
cancer, the above data demonstrate the ability of STI571
to interfere with other growth-stimulatory signaling path-
ways, such as EGF and FGF-2.
Effects of STI571 on growth factor-induced receptor and 
MAP kinase activation
A common cellular response to a variety of extracellular
signals involves the phosphorylation of corresponding
receptors and activation of the MAPK pathway. Therefore,
we evaluated whether the partial obstruction of EGF, FGF-
2, and IGF-1 signaling by STI571 was due to inhibition of
receptor- and/or MAPK phosphorylation. As shown in
Figure 4, treatment of growth factor-conditioned Mia-
PaCa-2 and T3M4 cells with STI571 did not inhibit activa-
tion of either MAPK or the EGFR. PDGF did not induce
PDGF and MAPK kinase phosphorylation in those cell
lines (data not shown).
To summarize, pancreatic cancer cells, resistant to growth
induction through STI571-sensitive c-kit and PDGF path-
ways, were still responsive to the inhibitory effects of
STI571, although at high GI50 concentrations. Since cell
cycle distribution as well as growth factor receptor and
MAPK-activation were not disturbed, we assumed that
antiproliferative effects of STI571 were apparently of a
toxic nature, the exact mechanism of which should be fur-
ther investigated.
Discussion
Protein kinases play a crucial role in signal transduction as
well as in cellular proliferation, differentiation, and vari-
ous regulatory mechanisms. Deregulation of those signal-
ing pathways is frequent during malignant
transformation. The inhibition of growth-related kinases,
especially tyrosine kinases, might provide new tools in the
therapy of cancer. The protein tyrosine kinase inhibitor
STI571, which has been effective in CML as well as GIST,
is a selective inhibitor of Abl, PDGF and c-kit receptor
tyrosine kinases [13,14,20]. This drug has a GI50 for inhi-
bition of Bcr-Abl kinase activity of 0.25 µM and inhibits
the growth of cell lines which are dependent on Bcr-Abl
kinase activity at 1 µM [13,14]. In addition, STI571 also
selectively inhibits the growth of cell lines derived from
CML patients, as well as primary CML progenitors in clo-
nogenic assays at low micromolar concentrations
[13,21,22]. It also efficiently inhibits SCF-mediated c-kit
activation at concentrations similar to those that inhibit
Bcr-Abl in cellular assays, with a GI50 in the range of 0.1–
0.5 µM [16].
In this study, we sought to extend the profile of STI571
applications, and tested its effects in pancreatic cancer cell
lines. The STI571 target c-kit and its ligand stem cell factorMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/32
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FACS analysis, Annexin-V and PI staining Figure 2
FACS analysis, Annexin-V and PI staining. Mia-PaCa-2 and T3M4 cell lines were cultured in complete medium overnight, 
and treated with GI50 concentrations of STI571 for 12 and 48 hours. Annexin and PI staining revealed increasing percentages of 
Annexin-positive and PI-positive cells with increasing time of STI571 incubation. Cell cycle analysis showed no changes in cell 
cycle distribution and no apoptosis (lower panel). The figure is representative of three independent experiments.
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Effect of STI571 on growth factor-induced cell proliferation Figure 3
Effect of STI571 on growth factor-induced cell proliferation. Mia-PaCa-2 and T3M4 cells were cultured in 1% FCS 
medium and incubated in the absence (solid circle) or presence (open triangle) of STI571 (at GI50 concentration for each cell 
line) and increasing concentrations of the indicated growth factors for 72 hours. Cell growth was determined by the MTT 
assay. Percent growth inhibition was calculated by comparison with control cell growth. Values shown are the mean ± SEM 
obtained from three independent experiments.
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Effect of STI571 on growth factor-induced MAPK phosphorylation Figure 4
Effect of STI571 on growth factor-induced MAPK phosphorylation. Mia-PaCa-2 and T3M4 cells were cultured in 1% 
FCS medium overnight, then treated with 10 ng/ml of the indicated growth factors and GI50 concentrations of STI571 for 5 
minutes. Phosphorylation of MAPK was determined by Western blot analysis with antibodies specific for phospho-p44/42 
MAPK. Equal loading was determined by stripping the membranes and blotting with an ERK2 (p42) antibody. The figure is rep-
resentative of three independent experiments.
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(SCF) have been shown to be expressed in pancreatic can-
cer cells. It has been shown that SCF has no significant
effects on pancreatic cancer cell growth [17], whereas
STI571 inhibits pancreatic cancer cell growth [17]. Thus,
STI571 may exert its effect on pancreatic cancer cell
growth through c-kit-independent pathways. For exam-
ple, STI571 can inhibit PDGF-mediated growth and leads
to the apoptosis of osteosarcoma cells in vitro by selective
inhibition of the PDGFR tyrosine kinase [15].
PDGF was one of the first polypeptide growth factors
identified that signals through a cell surface tyrosine
kinase receptor (PDGFR) to stimulate various cellular
functions, including growth, proliferation, and differenti-
ation. When PDGF binds to the extracellular portion of
the receptor, the receptor undergoes dimerization and
autophosphorylation with tyrosine kinase activation. To
date, PDGF expression has been shown in a number of
different solid tumors, from glioblastomas to prostate
carcinomas [23]. The biological role of PDGF signaling
can vary from autocrine stimulation of cancer cell growth
to more subtle paracrine interactions involving adjacent
stroma and angiogenesis. In pancreatic cancers, there is a
marked increase in the mRNA levels of PDGFR-alpha and
PDGFR-beta in comparison with the normal pancreas,
and PDGF and both PDGF receptors are present in the
cancer cells [12]. Thus, STI571 maybe also inhibit pancre-
atic cancer cell growth via the PDGF receptor pathway.
In pancreatic cancer, a variety of other growth factors that
signal through tyrosine kinase receptors are also expressed
at increased levels. For example, the presence of EGFs,
FGFs, PDGFs, and IGFs and their respective receptors has
been observed in pancreatic cancer, and these growth fac-
tors are thought to contribute to its malignant phenotype
[10,11,24]. For example, it has been reported that the
mRNA levels of EGF and EGFR are markedly increased in
pancreatic cancer tissues in comparison with the normal
pancreas [25], suggesting that the coexpression of EGFR
and its ligands may contribute to the aggressiveness of
human pancreatic cancer. FGF and its receptors are also
overexpressed in pancreatic cancer tissues and cell lines
[26,27], and cell growth, cell adhesion and invasion are
modulated by fibroblast growth factors in pancreatic can-
cer cell lines [27–29]. IGF-1 and its receptor IGF1R are
also overexpressed in pancreatic cancer [30], and they also
have the potential to stimulate pancreatic cancer cell
growth.
We have now demonstrated that STI571 has dose-depend-
ent inhibitory effects in all six tested pancreatic cancer cell
lines, with GI50 in the range of 17–31.5 µM (10% FCS)
and 9–20 µM (1% FCS). Notably, these concentrations
are relatively high compared with the concentrations
sufficient for the inhibition of Abl and c-kit in other
tumors [14,18,31]. Thus, when the drug was used in CML
patients, the plasma levels of STI571 inducing hemato-
logic and cytogenetic response in patients were reported
to be in the range of 0.17–5.68 µM after treatment with
25–600 mg STI571/day [19]. Concentrations of more
than 6 µM under cell culture conditions are unlikely to
translate into clinical practice, since the adverse effects of
the drug will become intolerable for the patients [32].
In cell cycle analysis we did not see cell cycle change and
apoptosis caused by STI571. It has been reported that
STI571 did not induce apoptosis in serum-containing
medium, and it has been suggested that this is because the
cells may be more resistant under these conditions, and
serum can persistently activate MAP kinase [16,33]. Based
on these data, we treated cells with STI571 in both com-
plete medium (10% FCS) and 1% FCS medium. No apop-
totic cell death was observed under either of these serum
concentrations, yet prolongation of STI571 treatment led
to more cell death under these conditions. In addition,
more Annexin-V-positive cells were also observed, sug-
gesting that STI571 can damage the integrity of the cell
membrane, causing phosphatidylserine translocation to
the outer surface of the cells, and at a late stage, causing
cell death without significant apoptosis. Thus, STI571
may exert its effects on cell growth in an unspecific
manner.
Conclusion
STI571 inhibits pancreatic cells growth, but these effects
are not mediated through blockage of the PDGF receptor
tyrosine kinase, since PDGF did not stimulate pancreatic
cancer cell growth and did not lead to MAP kinase or
PDGF receptor phosphorylation. In our previous study,
we excluded the SCF/c-kit tyrosine kinase receptor path-
way as a possible target of STI571 as well [17]. In the
present study, we demonstrate that STI571 partially but
not specifically blocks EGF, IGF-1 and FGF-2 mitogenic
pathways, which have the potential to stimulate pancre-
atic cancer cell growth. Since STI571 has relatively high
GI50 concentrations in pancreatic cancer cells, its action
appears to be of toxic origin and its clinical relevance in
pancreatic cancer is rather doubtful. Nevertheless, in view
of the extremely poor prognosis of patients with pancre-
atic cancer, and in view of the fact that pancreatic cancer
tissues in vivo indeed express both PDGF and c-kit receptor
tyrosine kinases, it seems worthwhile to further investi-
gate the therapeutic effects of STI571 in small clinical
trials.
Material and Methods
RPMI-1640 DMEM, trypsin-EDTA, and penicillin-strepto-
mycin were purchased from Invitrogen (Karlsruhe, Ger-
many); FBS from PAN Biotech (Aidenbach, Germany);
human recombinant PDGF, IGF-1 and FGF-2 from R&DMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/32
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Systems (Abingdon, United Kingdom), and EGF from
Upstate Biotechnology (Hamburg, Germany). Phospho-
PDGFR-beta (tyr857) and p-EGFR (tyr1173) polyclonal
antibodies were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Phospho-p44/42 MAPK
(Thr202/Tyr204) antibodies were purchased from Cell
Signaling Technology (Frankfurt, Germany), anti-rabbit
IgG HRPO-linked antibodies and ECL immunoblotting
detection reagents from Amersham Biosciences (Amer-
sham Life Science, Amersham, UK), and anti-goat IgG-
HPRO peroxidase linked antibodies from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA, USA). Complete mini-
EDTA-free protease inhibitor cocktail tablets and
Annexin-V-Fluos were purchased from Roche GmbH
(Mannheim, Germany). All other reagents were from
Sigma Chemical Company (Taufkirchen, Germany).
STI571 was kindly provided by Novartis Pharma AG
(Basel, Switzerland).
Cell culture and MTT assay
Human pancreatic cancer cell lines were routinely grown
in DMEM (Colo-357, and Mia-PaCa-2) or RPMI (Aspc-1,
BxPc-3, Capan-1, and T3M4) supplemented with 10%
FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin
(complete medium). To assess cell proliferation, the MTT
test was employed. Briefly, cells were seeded at a density
of 5000 cells/well in 96-well plates, grown overnight and
exposed to STI571 alone or in combination with growth
factors. After 48 or 72 hours of incubation, 3-(4, 5-meth-
ylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT)
was added (50 µg/well) for 4 hours. Formazan products
were solubilized with acidic isopropanol, and the optical
density was measured at 570 nm. To determine the GI50 of
STI571 (the concentration that causes 50% growth inhibi-
tion), graded concentrations of STI571 were added to trip-
licate wells and GI50 was calculated using 100 × (T-T0)/(C-
T0) = 50. T is the optical density of the test well after a 48-
hour period of exposure to STI571, T0 is the optical den-
sity at time zero, and C is the control optical density after
48 hours. All experiments were performed in triplicate.
FACS analysis of cell death and cell cycle
105 pancreatic tumor cells were seeded into 6-well plates
in 1% FBS-containing medium, allowed to adhere over-
night and then treated with corresponding GI50 concentra-
tions of STI571. To analyze cell cycle distribution, cells
were collected after 48 hours of incubation, washed with
PBS and resuspended in 0.5 ml of hypotonic PI buffer (5
µg/ml propidium iodide, 0.1% Triton X100 and 0.1%
sodium citrate), stored overnight at 4°C and then ana-
lyzed by flow cytometry using BD-LSR (Becton Dickinson
and Company, New York, USA). The resulting DNA histo-
grams were interpreted using the Cell Quest Pro software
(Becton Dickinson and Company, New York, USA). To
determine the degree of cell death, cells were collected
after 12, 24 and 48 hours of exposure to GI50 of STI571
and were washed and stained with Annexin-V-FITC
(apoptotic death) or PI (necrotic death) according to the
manufacturer's instructions (Roche, Mannheim,
Germany).
Western blot analysis
Cell culture monolayers were washed twice with ice-cold
PBS and lysed with buffer containing Tris-HCl (50 mM,
pH 7.4), NP-40 (1%), Na-deoxycholate (0.25%), NaCl
(150 mM), EDTA (1 mM), PMSF (1 mM), Na3VO4 (1
mM), NaF (1 mM) and one tablet of complete mini-
EDTA-free protease inhibitor cocktail (in 10 ml buffer).
Protein concentration was determined by the BCA protein
assay (Pierce Chemical Co., Rockford, IL, USA). 30 µg of
cell lysates were separated on SDS-polyacrylamide gels
and electroblotted onto nitrocellulose membranes. Mem-
branes were then incubated in blocking solution (5%
nonfat-milk in 20 mM Tris-HCl, 150 mM NaCl, 0.1%
Tween-20) (TBS-T), followed by incubation with the indi-
cated antibodies at 4°C overnight. The membranes were
then washed in TBS-T and incubated with HRPO-conju-
gated secondary antibodies for 1 hour at room tempera-
ture. Antibody detection was performed with an
enhanced chemiluminescence reaction.
Effect of STI571 on growth factor-induced EGFR  phosphorylation Figure 5
Effect of STI571 on growth factor-induced EGFR 
phosphorylation. Mia-PaCa-2 and T3M4 cell lines were 
cultured in 1% FCS medium overnight, then treated with 10 
ng/ml of EGF and GI50 concentrations of STI571 for 5 min-
utes. Phosphorylation of EGFR was determined by Western 
blot analysis with a phospho-EGFR-specific antibody. Equal 
loading was determined by stripping the membranes and 
blotting with an antibody to ERK2 (p42). The figure is repre-
sentative of three independent experiments.
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Statistical analysis
Results were expressed as mean ± SEM. For statistical anal-
ysis, the Student's t test was used. Significance was defined
as p < 0.05.
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